Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Pilleron S, Soto-Perez-de-Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601–608.
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Colaço A, Chaves R, et al. Chemical carcinogenesis. An Acad Bras Cienc. 2007;79(4):593–916.
   PubMed Web of Science ®Google Scholar
• Guo W, Tan HY, Chen F, et al. Targeting cancer metabolism to resensitize chemotherapy: potential development of cancer chemosensitizers from traditional Chinese medicines. Cancers. 2020;12:404.
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Bazarbashi S, Al Eid H, Minguet J. Cancer incidence in Saudi Arabia: 2012 data from the Saudi Cancer Registry. Asian Pac J Cancer Prev. 2017;18:2437–2444.
   PubMedGoogle Scholar
• Shahavi MH, Hosseini M, Jahanshahi M, et al. Evaluation of critical parameters for preparation of stable clove oil nanoemulsion. Arab J Chem. 2019;12(8):3225–3230.
   Web of Science ®Google Scholar
• Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.
   PubMed Web of Science ®Google Scholar
• Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429–439.
   PubMedGoogle Scholar
• Ali R, Arshad J, Palacio S, et al. Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug Des Devel Ther. 2019;13:569–580.
   PubMed Web of Science ®Google Scholar
• Bedi S, Khan SA, AbuKhader MM, et al. A comprehensive review on brigatinib – a wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharm J. 2018;26(6):755–763.
   PubMed Web of Science ®Google Scholar
• Hegde A, Hong DS, Behrang A, et al. Activity of brigatinib in crizotinib and ceritinib-resistant ROS1-rearranged non-small-cell lung cancer. JCO Precis Oncol. 2019;3:1–6.
   Web of Science ®Google Scholar
• Hirenkumar M, Steven S. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2012;3:1–19.
   Web of Science ®Google Scholar
• Muthu MS. Nanoparticles based on PLGA and its co-polymer: an overview. Asian J Pharm. 2009;3(4):266–273.
   Google Scholar
• Je YY, Jong MK, Kwang SS, et al. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng. 2005;15(4):279–288.
   PubMed Web of Science ®Google Scholar
• Hafezi Ghahestani Z, Alebooye Langroodi F, Mokhtarzadeh A, et al. Evaluation of anti-cancer activity of PLGA nanoparticles containing crocetin, artificial cells. Artif Cells Nanomed Biotechnol. 2017;45(5):955–960.
   PubMed Web of Science ®Google Scholar
• Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29(10):3867–3875.
   PubMed Web of Science ®Google Scholar
• Li S, Chun Zeng Y, Peng K, et al. Design and evaluation of glomerulus mesangium-targeted PEG-PLGA nanoparticles loaded with dexamethasone acetate. Acta Pharmacol Sin. 2019;40(1):143–150.
   PubMed Web of Science ®Google Scholar
• Hassan M, Farid D, Mahdi A, et al. Methotrexate-loaded PLGA nanoparticles: preparation, characterization and their cytotoxicity effect on human glioblastoma U87MG cells. Int J Med Nano Res. 2017;4(1):1–9.
   Google Scholar
• Fattahi A, Ghiasi M, Mohammadi P, et al. Preparation and physicochemical characterization of prazosin conjugated PLGA nanoparticles for drug delivery of flutamide. Braz J Pharm Sci. 2018;54(4):2–11.
   Web of Science ®Google Scholar
• Sabzichi M, Mohammadian J, Mohammadi M, et al. Vitamin D-loaded nanostructured lipid carrier (NLC): a new strategy for enhancing efficacy of doxorubicin in breast cancer treatment. Nutr Cancer. 2017;69(6):840–848.
   PubMed Web of Science ®Google Scholar
• Kim K-T, Lee J-Y, Kim D-D, et al. Recent progress in the development of poly(lactic-co-glycolic acid)-based nanostructures for cancer imaging and therapy. Pharmaceutics. 2019;11:280.
   PubMed Web of Science ®Google Scholar
• Andima M, Costabile G, Isert L, et al. Evaluation of β-sitosterol loaded PLGA and PEG-PLA nanoparticles for effective treatment of breast cancer: preparation, physicochemical characterization, and antitumor activity. Pharmaceutics. 2018;10:1–18.
   Web of Science ®Google Scholar
• Mohammed M, Alnafisah MS, Anwer MK, et al. Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer. J Polym Eng. 2019;39(10):909–916.
   Web of Science ®Google Scholar
• Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:1–17.
   Web of Science ®Google Scholar
• Alshahrani SM, Mohammad M, Khalid Anwer MD, et al. Temperature dependent solubility studies of brigatinib in some pure solvents useful in dosage form development. Acta Pol Pharm Drug Res. 2019;76(2):225–232.
   Web of Science ®Google Scholar
• Anwer MK, Mohammad M, Ezzeldin E, et al. Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. Int J Nanomedicine. 2019;14:1587–1595.
   PubMed Web of Science ®Google Scholar
• Mohamed AI, Abd-Motagaly AME, Ahmed OAA, et al. Investigation of drug–polymer compatibility using chemometric-assisted UV-spectrophotometry. Pharmaceutics. 2017;9:7.
   Web of Science ®Google Scholar
• Soltani S, Zakeri-Milani P, Barzegar-Jalali M, et al. Fabrication and in-vitro evaluation of ketotifen fumarate-loaded PLGA nanoparticles as a sustained delivery system. Iran J Pharm Res. 2017;16(1):22–34.
   PubMed Web of Science ®Google Scholar
• Jang J-H, Jeong S-H, Lee Y-B. Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery. Int J Mol Sci. 2019;20(13):3312.
   Web of Science ®Google Scholar
• Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019;12(7):908–931.
   Web of Science ®Google Scholar
• Wasiak I, Kulikowska A, Janczewska M, et al. Dextran nanoparticle synthesis and properties. PLOS One. 2016;11(1):e0146237.
   PubMed Web of Science ®Google Scholar
• Haider M, Elsherbeny A, Jagal J, et al. Optimization and evaluation of poly(lactide-co-glycolide) nanoparticles for enhanced cellular uptake and efficacy of paclitaxel in the treatment of head and neck cancer. Pharmaceutics. 2020;12:828.
   PubMed Web of Science ®Google Scholar
• Bahuguna A, Khan I, Bajpai VK, et al. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J Pharmacol. 2017;12(2):8–118.
   Web of Science ®Google Scholar
• Li X, Li F, Wang F, et al. Resveratrol inhibits the proliferation of A549 cells by inhibiting the expression of COX-2. Onco Targets Ther. 2018;11:2981–2989.
   PubMed Web of Science ®Google Scholar
• Amjadi I, Rabiee M, Hosseini MS. Anticancer activity of nanoparticles based on PLGA and its co-polymer: in-vitro evaluation. Iran J Pharm Res. 2013;12(4):623–634.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhang C. Tuning the size of poly (lactic‐co‐glycolic acid) (PLGA) nanoparticles fabricated by nanoprecipitation. Biotechnol J. 2018;13(1):1700203–1700219.
   Web of Science ®Google Scholar
• Jonderian A, Maalouf R. Formulation and in vitro interaction of rhodamine-B loaded PLGA nanoparticles with cardiac myocytes. Front Pharmacol. 2016;7:458.
   PubMed Web of Science ®Google Scholar
• Cao J, Choi JS, Oshi MA, et al. Development of PLGA micro- and nanorods with high capacity of surface ligand conjugation for enhanced targeted delivery. Asian J Pharm Sci. 2019;14(1):86–94.
   PubMed Web of Science ®Google Scholar
• Han FY, Thurecht KJ, Whittaker AK, et al. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Front Pharmacol. 2016;7:185.
   PubMed Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems – a review (part 2). Trop J Pharm Res. 2013;12(2):265–273.
   Google Scholar
• Yang Y, Bajaj N, Xu P, et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30(10):1947–1953.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Chakraborti CK, Behera PK, et al. FTIR and Raman spectroscopic investigations of a norfloxacin/carbopol934 polymeric suspension. J Young Pharm. 2012;4(3):138–145.
   PubMedGoogle Scholar
• Li F, Wen Y, Zhang Y, et al. Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles. Artif Cells Nanomed Biotechnol. 2019;47(1):4097–4108.
   PubMed Web of Science ®Google Scholar
• El Hady WEA, Mohamed EA, El-Aazeem Soliman OA, et al. In vitro–in vivo evaluation of chitosan–PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin. Int J Nanomedicine. 2019;14:7191–7213.
   PubMed Web of Science ®Google Scholar
• Fernando LP, Lewis JS, Evans BC, et al. Formulation and characterization of poly(propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles for pH-dependent membrane disruption and cytosolic delivery. J Biomed Mater Res A. 2018;106(4):1022–1033.
   PubMed Web of Science ®Google Scholar
• Zeng L, An L, Wu X. Modeling drug–carrier interaction in the drug release from nanocarriers. J Drug Deliv. 2011;2011:370308.
   PubMedGoogle Scholar
• Hines DJ, Kaplan DL. Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst. 2013;30(3):257–276.
   PubMed Web of Science ®Google Scholar
• Jo HY, Kim Y, Park HW, et al. The unreliability of MTT assay in the cytotoxic test of primary cultured glioblastoma cells. Exp Neurobiol. 2015;24(3):235–245.
   PubMed Web of Science ®Google Scholar
• Sajjadi SE, Ghanadian M, Haghighi M, et al. Cytotoxic effect of Cousinia verbascifolia Bunge against OVCAR-3 and HT-29 cancer cells. J HerbMed Pharmacol. 2015;4:15–19.
   Google Scholar